Skip to navigationSkip to contentSkip to footerHelp using this website - Accessibility statement

Equity markets


ASX is set to slip.

ASX drops; Azure jumps 42pc; Whitehaven poised to cop strike

Shares fall; US tech stocks dive after earnings shortfall from Alphabet; Westpac’s Ellis tips RBA to raise cash rate on Cup day; SQM to buy Azure for $1.6 billion; Fortescue makes slow start on push for fifth iron ore export record. Follow here for more.

  • 1 hr ago
  • Joanne Tran, Timothy Moore, Cecile Lefort, Joshua Peach and Vesna Poljak
Wall Street.

ASX to slip; Wall St drops after mixed Microsoft and Alphabet results

Australian shares are poised to slip. Wall Street is falling after mixed profit reports from Microsoft and Alphabet. Oil was volatile.


Shopping in Paris: economic indicators in the eurozone are weakening in the face of higher borrowing costs.

Gucci sales fall as Kering lags peers facing luxury slowdown

Demand for Balenciaga is still suffering from the fallout over an ad campaign scandal last year.

  • Angelina Rascouet
RBA governor Michele Bullock on Tuesday night.

‘Assertive’ and ‘transparent’: Economists applaud Bullock’s speech

Economists witnessed Reserve Bank governor Michele Bullock’s inflation fighting credentials first-hand on Tuesday night in her maiden speech in the top job.

  • Joanne Tran
Local shares are poised to rise at the open.

ASX ends flat after hot CPI; economists up RBA rate rise bets

Australia’s September quarter CPI reading beats economists forecasts. Real estate stocks fall and iron ore miners rally. Follow updates here.

  • Updated
  • Timothy Moore, Joshua Peach, Joanne Tran and Cecile Lefort
Wall Street.

ASX to rise, Wall Street lifted by data, earnings

Australian shares are set to open higher. Bonds steady after rout. Bitcoin rallies. Microsoft rises, Alphabet falls on quarterly results.

  • Updated
  • Timothy Moore

This Month

Mission: Impossible – Dead Reckoning Part One, which was released in July, generated close to $US600 million ($944 million) in ticket sales worldwide.

Paramount delays ‘Mission Impossible’ to 2025 amid actors’ strike

The delay of the eighth title in the Mission: Impossible franchise strips parent Paramount Global of an important box office and streaming title next year.

  • Thomas Buckley
Local shares are poised to open lower as risk aversion rises.

ASX rises; Lynas, Zip shares climb; Ansell drops

Shares finish higher as investors shrugged off wild movements in the bond market; Ansell says pandemic unwind still has a way to go; Bitcoin leaps through $US31,000. Follow updates here.

  • Updated
  • Timothy Moore, Joanne Tran, Cecile Lefort, Joshua Peach and Vesna Poljak
Ali Dibadj says rocky markets should be “nirvana” for an active manager.

Janus Henderson CEO’s three planks for risky markets

Ali Dibadj says uncertain markets are “nirvana” for the global asset manager, which is in the midst of a turnaround.

  • Updated
  • James Thomson
First Sentier’s Australian equities fund topped Mercer’s returns leaderboard for the 12 months to September 30.

Pricing power delivers First Sentier growth fund Mercer prize

Australian equities geared fund ranked No.1 despite the worst performance over the past quarter among Mercer’s top 10.

  • Updated
  • Joshua Peach
Bill Ackman has closed his bond short, warning of a slowing US economy.

How Bill Ackman set off a wild night on markets

The legendary Wall Street hedge fund billionaire announced that he had covered his short in a night of bond market turbulence where the 10-year Treasury yield hit 5 per cent before plunging.

  • James Thomson
Wall Street.

ASX to fall, bond volatility persists, Bullock speech on radar

Australian shares are set to open lower, tracking late session weakness in New York. US yields spiked higher, then tumbled. Bitcoin leaps.

  • Timothy Moore
Morgan Stanley’s Mike Wilson expects the S&P 500 to end the year at 3900.

Morgan Stanley’s Wilson says profit estimates are too high

The odds of a year-end rally in US stocks are fading as investors face a multitude of risks, according to Morgan Stanley’s Michael Wilson.

  • Sagarika Jaisinghani
Growing Middle East tensions have fuelled a record price in gold.

Profit outlook brightens on gold’s $A record

The gold price’s record high in Australian dollars arrives as the currency falls to US63.2¢ and domestic producers eye higher profit margins.

  • Updated
  • Tom Richardson
Mining stocks are on track to record a third consecutive month of losses.

Mining stocks on track for third month of losses as China woes deepen

The ASX’s heavyweight materials sector is facing its longest losing streak since 2021 as worries about global growth offset the incredible run in iron ore.

  • Joanne Tran
Local shares are poised to drop.

ASX drops to one-year low as South32 disappoints

Shares tumble; Judo seeks $75 million hybrids, South32 flags 33 per cent drop in coal output; bond yields at 12-year highs; Immutep with positive trial results; Propel Funerals rejects buy offers.

  • Updated
  • Timothy Moore, Cecile Lefort, Joanne Tran, Joshua Peach and Vesna Poljak
Surging bond yields may have finally hit the ASX.

The ASX 200 has gone nowhere for 16 years

It’s not just bond yields testing levels not seen since just before the GFC. The ASX 200 is back where it was in November 2007, as Wall Street faces a crucial test.

  • James Thomson
China has agreed to a five-month review of its Australian wine tariff.

Treasury Wine investors brace for slow return to China shelves

The potential end of Chinese tariffs on Australian wines is buoying its shares. But a sales recovery to the mainland may take longer than some expect.

  • Joshua Peach
LHC Capital’s Marcus Hughes.

This hedge fund shorted Qantas as Joyce was selling

Marcus Hughes followed Alan Joyce’s lead. He shorted the stock, betting the value of Qantas shares would fall. “Whenever an insider sells, we’ll look at shorting a company.” It worked.

  • Joanne Tran
Sector heavyweight CSL has fallen over 20 per cent in the last six months.

Unloved healthcare stocks can reinvent themselves

Those betting on the demise of blue-chip healthcare stocks such as CSL and ResMed might want to rethink based on a review of Microsoft and Apple’s histories.

  • Jun Bei Liu